Neauvia has shared its success at the AMWC 2024 Awards held in Monaco. The company received the “Best Injectable Dermal Filler” award for its innovative product, Stimulate, a unique PEG-HA + CaHA filler.
The AMWC Awards, respected for their commitment to acknowledging innovation and excellence in the global medical aesthetic market, spotlighted Neauvia as a leader in injectable dermal fillers.
Winners were announced at the AMWC Congress on March 27, 2024. This recognition, conferred by a panel of esteemed jurors and open for voting by all professionals in the medical aesthetics community, reaffirms Neauvia’s dedication to rethinking medical aesthetics.
“We are proud to receive this renowned award and acknowledgment. These achievements highlight Neauvia’s Red Team dedication and our commitment to innovation in the Medical Aesthetics landscape.” said Gabriele Drigo, founder and chief executive of Neauvia.
Stimulate is an injectable made of hyaluronic acid (HA) cross-linked with PEG, enriched with glycine, L-proline and calcium hydroxyapatite (CaHA). Its advanced formulation has been demonstrated to effectively address skin and subcutaneous tissue concerns, in particular, the correction of disorders and the correction of mid-face volume deficit.1 The collected data highlight an efficient mechanical effect of the PEGylated polymeric acid matrix enriched with CaHA, aligning with other evidence in vitro and in vivo.1
Professor Nicola Zerbinati, dermatologist and Neauvia chief scientific officer, shared her thoughts, “Through Stimulate, Neauvia showcases its continuous dedication to pioneering research, development, and medical excellence. Trusted by thousands of doctors worldwide, Stimulate epitomizes Neauvia’s commitment, delivering patient satisfaction with its safety and efficacy.”
Neauvia remains steadfast in its mission to lead the Medical Aesthetics industry with cutting-edge products and unwavering commitment to enhancing healthcare practitioners’ capabilities worldwide.
